87. Polygenic risk scores in kidney transplantation. Curr Opin Organ Transplant. 2025 (in press)
Jelencsics K, Oberbauer R.
// Publications
86. [Nomenclature for kidney function and kidney diseases – Improving assessment and prognosis through precision and comprehensibility]. Dtsch Med Wochenschr. 2022, 147(21):1398-1406
Eckardt KU, Binet I, de Groot K, Floege J, Galle JC, Jordans I, Kribben A, Oberbauer R, Pavenstädt H, Rosenkranz A, Säemann M, Winkelmayer WC
85. Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease. Curr Opin Nephrol Hypertens 2022, 31(4):339-343
Dörr K, Kainz A, Oberbauer R.
84. Prediction models for living organ transplantation are poorly developed, reported and validated: a systematic review. J Clin Epidemiol. 2022, 145:126-135
Haller MC, Aschauer C, Wallisch C, Leffondré K, van Smeden M, Oberbauer R, Heinze G
83. Viewpoint article: Organ transplants of the future: planning for innovations including xenotransplantation. Transplant Int 2021, 34(11):2006-2018
Cozzi E, Schneeberger S, Bellini MI, Berglund E, Böhmig G, Fowler K, Hoogduijn M, Jochmans I, Marckmann G, Marson L, Neuberger J, Oberbauer R, Pierson RN 3rd, Reichart B, Scobie L, White C, Naesens M; ESOT Workstream 1 of the TLJ (Transplantation Learning Journey) project.
82. Renal Delivery of Pharmacologic Agents During Machine Perfusion to Prevent Ischaemia-Reperfusion Injury: From Murine Model to Clinical Trials. Front Immunol. 2021, 12:673562
Franzin R, Stasi A, Fiorentino M, Simone S, Oberbauer R, Castellano G, Gesualdo L
81. Precision medicine in transplantation and hemodialysis. Nephrol Dial Transplant. 2021, 36(Supplement_2):31-36
Oberbauer R, Meyer TW.
.
80. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplant Rev (Orlando). 2020, 34(2):100531
Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L, Budde K.
79. COVID-19 and renal transplantation. Nephrologe 2021, 28:1-8.
Regele F, Oberbauer R.
78. Response to: “Biostatistics pitfalls: Lessons learned from analysis of medical data” by Yin et al. Contemp Clin Trials. 2020, 89:105916
Reindl-Schwaighofer R, Heinzel A, Heinze G, Kammer M, Oberbauer R
77. Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times. 2019, 34(8):1292-1300.
Watschinger B, Budde K, Crespo M, Heemann U, Hilbrands L, Maggiore U, Mariat C, Oberbauer R, Oniscu GC, Peruzzi L, Sorensen SS, Viklicky O, Abramowicz D; ERA-EDTA DESCARTES Working Group.
76. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020, 104(4):708-714
Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Balk EM, Gordon CE, Earley A, Rofeberg V, Knoll GA
75. Deceased donor kidney allocation schemes and international exchange. Curr Opin Organ Transplant. 2020, 25(1):66-73
Heemann U, Oberbauer R, Sprangers B, Gökalp C, Bemelman F; Eurotransplant Kidney Advisory Committee.
74. Novel insights into Non-HLA Alloimmunity in Kidney Transplantation. Transpl Int. 2020, 33:5-17
Reindl-Schwaighofer R, Heinzel A, Gualdoni GA, Mesnard L, Claas FHJ, Oberbauer R.
73. To test or to estimate? P-values versus effect sizes. Transpl Int. 2020, 33(1):50-55
Dunkler D, Haller M, Oberbauer R, Heinze G.
72. Histocompatibility: minor differences have a major impact. Nat Rev Nephrol. 2019, 15(9):529-530.
Reindl-Schwaighofer R, Oberbauer R.
71. How to increase kidney transplant activity throughout Europe-an advocacy review by the European Kidney Health Alliance. Nephrol Dial Transplant. 2019, 34(8):1254-1261
Vanholder R, Stel VS, Jager KJ, Lameire N, Loud F, Oberbauer R, de Jong RW, Zoccali C.
70. Normal and pathologic erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018, 103(10):1593-1603
Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O
69. Dialysis vintage and outcomes in renal transplantation. Nephrol Dial Transplant 2019, 34(4):555-560
Haller M, Kammer M, Oberbauer R
68. Strategies for long-term preservation of kidney graft function. The Lancet 2017, 389: 2152–62
Wekerle T, Segev D, Lechler R, Oberbauer R
67. Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. Nephrol Dial Transplant. 2018, 3(10):1699-1707
Abramowicz D, Oberbauer R, Heemann U, Viklicky O, Peruzzi L, Mariat C, Crespo M, Budde K, Oniscu GC.
66. Optimizing hypertension management in renal transplantation: a call to action. Nephrol Dial Transplant 2017, 32(12):1959-1962
Halimi JM, Persu A, Sarafidis PA, Burnier M, Abramowicz D, Sautenet B, Oberbauer R, Mallamaci F, London G, Rossignol P, Wuerzner G, Watschinger B, Zoccali C
65. An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int. 2018, 31:125-130
Gleiss A, Oberbauer R, Heinze G
64. Mechanisms underlying human genetic diversity: consequence for anti-graft antibody responses. Transpl Int 2018, 31(3):239-250
Reindl-Schwaighofer R, Heinzel A, Signorini L, Thaunat O, Oberbauer R.
63. Immunological Consequences of Kidney Cell Death. Cell Death & Disease, 2018, 25;9(2):114.
Sarhan M, von Mässenhausen A, Hugo C, Oberbauer R, Linkermann A
62. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017, 13(7):393-409
Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Biesen WV, Zoccali C; European Kidney Health Alliance.
61. Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease: A Literature Review and Position Statement on Behalf of the European Renal Association-European Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice. Transplantation 2016, 100(10):e55-65
Segall L, Nistor I, Pascual J, Mucsi I, Guirado L, Higgins R, Van Laecke S, Oberbauer R, Van Biesen W, Abramowicz D, Gavrilovici C, Farrington K, Covic A
60. Combating costs of CKD while delivering high quality health care: a health economic call to action. Nature Reviews Nephrology 2017, 13(7):393-409
Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart J, Lameire N, Morton R, Oberbauer R, Postma M, Tonelli M, Van Biesen W, Zoccali C
59. Editorial: Progression of Interstitial Fibrosis in Kidney Transplantation. CJASN 2016, 11(12):2110-2112
Oberbauer R
58. Transplantation in Austria, Transplantation 2016, 100:1785-1787
Berlakovich GA, Zuckermann A, Schneeberger S, Rosenkranz AR, Oberbauer R
57. Immunosuppression in the elderly renal allograft recipient: a systematic review. Transplant Rev 2016, 30(3):144-53
Montero N, Pérez-Sáez MJ, Pascual J, DESCARTES Working Group, DESCARTES ERA-EDTA Board, Abramowicz D, Budde K, Dudley C, Hazzan M, Klinger M, Maggiore U, Oberbauer R, Pascual J, Sorensen SS, Viklicky O
56. Does pre-emptive transplantation vs post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes working group and ERBP. Nephrol Dial Transplant 2016,31(5):691-697
Abramowicz D, Hazzan M, Maggiore U, Peruzzi L, Cochat P, Oberbauer R, Haller M, Van Biesen W for the Descartes working group and the European Renal Best Practice (ERBP) advisory board
55. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. NDT 2015, 30 (suppl 4):iv105-iv112.
Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, Mayer B
54. Molecular disease presentation in diabetic nephropathy. NDT 2015, 30 (suppl 4):iv17-iv25.
Heinzel A, Mühlberger I, Stelzer G, Lancet D, Oberbauer R, Martin M, Perco P.
53. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. NDT 2015, 30 (suppl 4):iv86-iv95
Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ
52. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. NDT 2015, 30 (suppl 4):iv113-iv118. (IF 4.8)
Kainz A, Hronsky M, Stel VS, Jager KJ, Geroldinger A, Dunkler D, Heinze G, Tripepi G, Oberbauer R
51. Population Attributable Fraction of Modifiable Lifestyle Factors for Chronic Kidney Disease and Mortality in Individuals with Diabetes. NDT Supp 2015 (in press)
Dunkler D, Kohl M, Mann, Teo, Yusuf, Oberbauer R
50. Genome-wide Studies to Identify Risk Factors for Kidney Disease with a Focus on Patients with Diabetes. NDT 2015, 30 (suppl 4):iv26-iv34 (IF 4.8)
Regele F, Jelencsics K, Shiffman D, Pare G, McQueen MJ, Mann JEF, Oberbauer R
49. microRNAs in Kidney Transplantation. Nephrol Dial Transplant 2015; 30(6):910-917.
Wilflingseder J, Reindl-Schwaighofer R, Sunzenauer J, Kainz A, Heinzel A, Mayer B, Oberbauer R
48. Strategies to increase the donor pool and access to kidney transplantation: an international perspective. Nephrol Dial Transplant. 2015 Feb;30(2):217-22
Maggiore U, Oberbauer R, Pascual J, Viklicky O, Dudley C, Budde K, Schwartz Sorensen S, Hazzan M, Klinger M, Abramowicz D for the ERA-EDTA-DESCARTES working group
47. Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art. BMC Nephrol. 2014 Mar 14;15(1):45
Boucquemont J, Heinze G, Jager KJ, Oberbauer R, Leffondre K.
46. Health economics and European Renal Best Practice – is it time to bring health economics into evidence-based guideline production in Europe? Nephrol Dial Transplant. 2014 Nov;29(11):1994-7
Haller MC, Vanholder R, Oberbauer R, Zoccali C, Van Biesen W.
45. Blood disorders after kidney transplantation. Transplant Rev (Orlando). 2014 Apr;28(2):63-75.
Reindl-Schwaighofer R, Oberbauer R.
44. Anemia and Erythrocytosis in patients after kidney transplantation. Transpl Int 2012, 25:1013-1023
Malyszko J, Oberbauer R, Watschinger B.
43. Integrative Analysis of -Omics Data and Histologic Scoring in Renal Disease and Transplantation: Renal Histogenomics. Neph Sem 2010, 30:520-530
Perco P, Oberbauer R.
42. Renal phosphate handling in human – what can we learn from hereditary hypophosphatemias? Europ J Clin Invest 2010, 40:552-560
Amatschek S, Haller M, Oberbauer R.
41. mTOR inhibition: the learning curve in kidney transplantation. Transpl Int 2010, 23:447-460
Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, Oberbauer R, Kahan BD.
40. Biomarkers in Renal Transplantation Ischemia Reperfusion Injury. Transplantation 2009 88(3S):S14-S19
Mühlberger I, Perco P, Fechete R, Mayer B, Oberbauer R.
39. Protocol Conversion From a Calcineurin Inhibitor Based Therapy to Sirolimus. Transplantation 2009, 87(8S):S7-S10
Oberbauer R.
38. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. Transpl Int. 2009, 22:69-77
Haller M, Oberbauer R.
37. Biomarkers—A Potential Route for Improved Diagnosis and Management of Ongoing Renal Damage. Transplant Proc. 2008, 40(10 Suppl):S44-S47
Oberbauer R.
36. Kidney injury molecule-1 as a biomarker of acute kidney injury in renal transplant recipients Nat Clin Pract Nephrol. 2008, 4:362-363
Perco P, Oberbauer R.
35. Bone disease after kidney transplantation . Transpl Int. 2008, 21:615-624
Mitterbauer C, Oberbauer R.
34. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: A systems biology perspective. J Cell Mol Med 2008, 12:1177-1187
Perco P, Wilflingseder J, Bernthaler A, Wiesinger M, Rudnicki M, Wimmer B, Mayer B, Oberbauer R.
33. Säure-Basenhaushalt. Wien Klin Wochenschr. 2007, 119(5-6 Suppl 1):21-38.
Schwarz C, Oberbauer R.
32. Calcineurin sparing in renal transplantation. Curr Opin Transplant 2006, 11:632-636
Schwarz C, Oberbauer R.
31. Protein biomarkers associated with acute renal failure and chronic kidney disease. Europ J Clin Invest 2006, 36:753-763
Perco P, Pleban C, Kainz A, Lukas A, Mayer G, Mayer B, Oberbauer R.
30. Gene expression and biomarkers in renal transplant ischemia reperfusion injury. Transplant Int 2007, 20:2-11
Perco P, Pleban C, Kainz A, Lukas A, Mayer B, Oberbauer R.
29. Developments in clinical islets, liver thoracic, kidney and pancreas transplantation in the last 5 years. Am J Transplant 2006, 6:1759-1767
Feng S, Barr M, Roberts J, Oberbauer R, Kaplan B.
28. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006, 36:13-22
Schwarz C, Sulzbacher I, Oberbauer R.
27. Transforming omics data into context: Bioinformatics on genomics and proteomics raw data. Electrophoresis 2006, 27:2659-2675
Perco P, Rapberger R, Siehs C, Lukas A, Oberbauer R, Mayer G, Mayer B.
26. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant. 2005, 5:3023.
Oberbauer R.
25. Improved renal function in de novo renal transplant patients on sirolimus maintenance therapy following discontinuation of cyclosporine. Therapeutic Drug Monitoring 2005, 27:7-9
Oberbauer R.
24. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 2004, 35:1229-1239
Bielesz B, Klaushofer K, Oberbauer R.
23. Health related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes 2004
Fiebiger W, Mitterbauer C, Oberbauer R.
22. Biochemical marker of renal osteodystrophy. Kidney and Blood Press Res 2003 (in press)
Schwarz C, Oberbauer R.
21. Sirolimus-immunosuppression with improved renal function in kidney transplantation. Organs And Tissues 2003, 2:85-91
Oberbauer R.
20. The influence of organ donor factors on early allograft function. Curr Opin Urol. 2003, 13:99-104
Schwarz C, Oberbauer R.
19. Mitochondrial regulation of apoptosis. News in Physiol Sci 2003, 18:89-94
Mayer B, Oberbauer R.
18. Akutes Nierenversagen auf zellulärer Ebene. Nephroscript 2002
Bielesz B, Oberbauer R.
17. Tubular apoptosis in the pathophysiology of renal disease. Mid Europ Med, Review 2002, 15-16:671-677
Hauser P, Oberbauer R.
16. Dialysis access-current practice. Am J Kidney Dis 2002, 39:208
Oberbauer R.
15. Rational decision making in the treatment of renal artery stenosis. Mid Europ Med, Editorial 2002
Mitterbauer C, Oberbauer R.
14. The impact of immunosuppressant nephrotoxicity. Hospital Prescriber Europe 2002, 2: 68-71
Oberbauer R.
13. The future of mTOR inhibitors. Current Opin Urol 2002, 12:109-113
Schwarz C, Oberbauer R.
12. Neue Immunsuppressiva nach Nierentransplantation. Nephroscript 2001, 14: ed. Oberbauer R.
Oberbauer R.
11. Isoliert systolische Hypertonie im Alter. Forum Dr Med 2001
Schwarz C, Oberbauer R.
10. Hypertonie im Alter. Nephroscript 2000, 12:4
Oberbauer R.
9. Die Effekte von Blutzucker- und Blutdruckeinstellung auf die Progression der diabetischen Nephropathie. Mid Europ J Med 2000, 112:907-911
Schwarz C, Oberbauer R.
8. Osteoporosetherapie und Nierenfunktion – worauf zu achten ist. Nephroscript 2000, 1: 15-20, ed. Oberbauer R.
Weidekamm C, Oberbauer R.
7. Pathophysiology of acute renal failure on a cellular level. Mid Europ J Med 2000, 112: 5-15
Schwarz G, Gruber U, Oberbauer R.
6. Bacterial and fungal infections after kidney transplantation. Curr Opin Urol 1999, 9:45-49
Schmidt A, Oberbauer R.
5. Chronisches Nierentransplantatversagen – chronische Abstoßung. Spektrum der Nephrologie 1997, 6: 15-22
Oberbauer R.
4. Not nonsense but antisense – applications of antisense oligonucleotides in different fields of medicine. Mid Europ J Med 1997, 109: 40-46
Oberbauer R.
3. Proteinuria as a consequence of altered glomerular permselectivity. Clin Nephrol 1996, 46: 357-361
Oberbauer R, Haas M, Mayer G.
2. Antisense and the kidney. Kidney and Blood Press Res 1996, 19: 221-224
Oberbauer R, Murer H, Schreiner GF, Meyer TW.
1. Cuprophan and polysulfone induce apoptosis in neutrophils in the presence of serum. Kidney Int Supp 2001, 59, S-216 – S220l
Rosenkranz A, Pehersdorfer E, Körmöczi GF, Zlabinger GJ, Mayer G, Hörl WH, Oberbauer R.